Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States

Cited by (772)

Items 401–500 of 772

1. Ultrasonography-diagnosed non-alcoholic fatty liver disease is not associated with prevalent ischemic heart disease among diabetics in a multiracial Asian hospital clinic population
   Wah‐Kheong Chan, Alexander Tong Boon Tan, Shireene Ratna Vethakkan, Pei‐Chien Tah, Anushya Vijayananthan, Khean‐Lee Goh · 2014 · Clinics and Research in Hepatology and Gastroenterology
2. Association between non‐invasively diagnosed hepatic steatosis and chronic kidney disease in C hinese adults on their health check‐up
   Jing Zeng, Chao Sun, Wan Lu Sun, Guang Yu Chen, Qin Pan, Shi Yan Yan, Zheng Jie Xu, Yuanwen Chen, Jian‐Gao Fan · 2017 · Journal of Digestive Diseases
3. Non‐invasive fibrosis markers are associated with mortality risk in both general populations and non‐alcoholic fatty liver disease patients
   Xianhua Mao, Zhenqiu Liu, Oumin Shi, Kangkang Yu, Yanfeng Jiang, Jin Li, Tiejun Zhang, Xingdong Chen · 2020 · Hepatology Research
4. Management of NAFLD patients with advanced fibrosis
   Douglas Maya‐Miles, Javier Ampuero, Rocío Gallego‐Durán, Paola D’Ingianna, Manuel Romero‐Gómez · 2021 · Liver International
5. End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease
   Arun Jayant Sanyal, Brent A. Neuschwander‐Tetri, James A. Tonascia · 2015 · Gastroenterology
6. Liver Steatosis: A Marker of Metabolic Risk in Children
   Costanza Renata Neri, Serena Scapaticci, Francesco Chiarelli, Cosimo Giannini · 2022 · International Journal of Molecular Sciences
7. Metabolic-associated fatty liver disease and the risk of cardiovascular disease
   Pengwei Zhang, Xianhui Dong, Wei Zhang, Shiyin Wang, Chen Chen, Jiake Tang, Yao You, Siqi Hu, Shenghui Zhang, Chunyi Wang et al. · 2022 · Clinics and Research in Hepatology and Gastroenterology
8. Oxidized Low-Density Lipoproteins Trigger Hepatocellular Oxidative Stress with the Formation of Cholesteryl Ester Hydroperoxide-Enriched Lipid Droplets
   Iku Sazaki, Toshihiro Sakurai, A Yamahata, Sumire Mogi, Nao Inoue, Koutaro Ishida, Ami Kikkai, Hana Takeshita, Akiko Sakurai, Yuji Takahashi et al. · 2023 · International Journal of Molecular Sciences
9. The predictive role of the platelet-to-lymphocyte ratio for the risk of non-alcoholic fatty liver disease and cirrhosis: a nationwide cross-sectional study
   Cheng Yan, Weichang Zhang, Yangyan Xiao, Yuxin Sun, Xinke Peng, Wenwu Cai · 2024 · Frontiers in Endocrinology
10. Targeting acetyl-CoA carboxylases for the treatment of MASLD
    María Antonia Mateo-Marín, Michele Alves‐Bezerra · 2024 · Journal of Lipid Research
11. Nonalcoholic fatty liver disease and cardiovascular disease phenotypes
    Giandomenico Bisaccia, Fabrizio Ricci, Cesare Mantini, Claudio Tana, Gian Luca Romani, Cosima Schiavone, Sabina Gallina · 2020 · SAGE Open Medicine
12. Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand
    Pochamana Phisalprapa, Ratthanon Prasitwarachot, Chayanis Kositamongkol, Pranaidej Hengswat, Weerachai Srivanichakorn, Chaiwat Washirasaksiri, Sombat Treeprasertsuk, Phunchai Charatcharoenwitthaya, Nathorn Chaiyakunapruk · 2021 · BMC Gastroenterology
13. Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care
    Laurence J. Dobbie, Mohamed Kassab, Andrew Davison, Pete Grace, Daniel James Cuthbertson, Theresa Hydes · 2021 · Journal of Clinical Medicine
14. When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD
    Alba Rojano‐Toimil, Jesús Rivera‐Esteban, Ramiro Manzano-Núñez, Juan Bañares, David M. Selva, Pablo Gabriel-Medina, Roser Ferrer, Juan Manuel Pericàs, Andreea Ciudin · 2022 · Journal of Clinical Medicine
15. Theaphenon E prevents fatty liver disease and increases CD4+ T cell survival in mice fed a high-fat diet
    Heidi Coia, Ning Ma, Yanqi Hou, Eva Permaul, Deborah L. Berry, Maria Idalia Cruz, Evan L. Pannkuk, Michael J. Girgis, Zizhao Zhu, Yichen Lee et al. · 2020 · Clinical Nutrition
16. Depression in nonalcoholic fatty liver disease and all-cause/cause-specific mortality
    Kim, Donghee, Manikat, Richie, Shaikh, Anjiya, Cholankeril, George, Ahmed, Aijaz · 2024 · European Journal of Clinical Investigation
17. Non‐invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study
    Sheila M. Grecian, Stela McLachlan, Jonathan Andrew Fallowfield, Patrick K. A. Kearns, Peter Clive Hayes, Indra Neil Guha, Joanne R Morling, Stephen Glancy, Rachel M. Williamson, Rebecca M. Reynolds et al. · 2020 · Liver International
18. Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis
    Nicole Cianci, Mohsan Subhani, Trevor Hill, Amardeep Khanna, Dong Zheng, Abhishek Sheth, Colin John Crooks, Guruprasad Padur Aithal · 2022 · World Journal of Hepatology
19. Risk of Liver Fibrosis Is Associated with More Severe Strokes, Increased Complications with Thrombolysis, and Mortality
    Emma Min Shuen Toh, Priscilla Roshini Joseph Ravi, Chua Ming, Amanda Yuan Ling Lim, Ching‐Hui Sia, Bernard P.L. Chan, Vijay Kumar Sharma, Cheng Han Ng, Eunice Xiang Xuan Tan, Leonard L.L. Yeo et al. · 2023 · Journal of Clinical Medicine
20. Shorter leucocyte telomere length as a potential biomarker for nonalcoholic fatty liver disease-related advanced fibrosis in T2DM patients
    Kun Dong, Ye Zhang, Jiaojiao Huang, San-Shan Xia, Yan Yang · 2020 · Annals of Translational Medicine
21. Prognostic durability of liver fibrosis tests and improvement in predictive performance for mortality by combining tests
    Sandrine Bertrais, Jérôme Boursier, Alexandra Ducancelle, Frédéric Oberti, Isabelle Fouchard‐Hubert, Valérie Moal, Paul Calès · 2016 · Journal of Gastroenterology and Hepatology
22. The Effect of Testosterone Replacement Therapy on Nonalcoholic Fatty Liver Disease in Older Hypogonadal Men
    Hae Seung Lee, Sang Hun Han, Ronald S. Swerdloff, Youngju Pak, Matthew Jay Budoff, Christina Wang · 2023 · The Journal of Clinical Endocrinology & Metabolism
23. Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation
    Si-hua Tan, Xiaoli Zhou · 2023 · Clinics
24. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe
    Tracey G. Simon, Kathleen E. Corey, Raymond T. Chung, Robert Patrick Giugliano · 2016 · Digestive Diseases and Sciences
25. End-points for drug treatment in NASH
    Leon Anton Adams · 2019 · Hepatology International
26. Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model
    Julie Hviid Klæbel, M. Kriegbaum Skjodt, Josephine Skat‐Rørdam, Günaj Rakipovski, David Højland Ipsen, Anne Marie V. Schou‐Pedersen, Jens Lykkesfeldt, Pernille Tveden‐Nyborg · 2019 · Nutrients
27. Increased Prevalence of Obesity and Metabolic Syndrome in Patients with Alcoholic Fatty Liver Disease
    Amandeep Singh, Hina Amin, Rajat Garg, Mohit Gupta, Rocío López, Naim Alkhouri, Arthur J. McCullough · 2020 · Digestive Diseases and Sciences
28. Long-Term Outcomes of Nonalcoholic Fatty Liver Disease
    Min‐Sun Kwak, Donghee Kim · 2015 · Current Hepatology Reports
29. Association of Non-Alcoholic Fatty Liver Disease and Hepatic Fibrosis with Epicardial Adipose Tissue Volume and Atrial Deformation Mechanics in a Large Asian Population Free from Clinical Heart Failure
    Yau‐Huei Lai, Cheng‐Huang Su, Ta‐Chuan Hung, Chun‐Ho Yun, Cheng‐Ting Tsai, Hung‐I Yeh, Chung‐Lieh Hung · 2022 · Diagnostics
30. Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV , a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin
    Karen D. Corbin, Samuel E. Dagogo-Jack, Christopher Paul Cannon, David Z.I. Cherney, Francesco Cosentino, Robert C. Frederich, Jie Liu, Annpey Pong, Jianxin Lin, Nilo B. Cater et al. · 2022 · Diabetes Obesity and Metabolism
31. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association
    Atul Deep Bali, Akiva Rosenzveig, William H. Frishman, Wilbert S. Aronow · 2023 · Cardiology in Review
32. Predictive value of liver fibrosis scores in cardiovascular diseases among hypertensive population
    Shengjun Xiong, Shizhang Yin, Wanshu Deng, Yuanhui Zhao, Wenhang Li, Pengbo Wang, Zhao Li, Hongmei Yang, Ying Zhou, Shasha Yu et al. · 2023 · Journal of Hypertension
33. Predicting liver-related events in NAFLD: A predictive model
    Luis Calzadilla Bertot, Gary P. Jeffrey, Zhengyi Wang, Yi Huang, George Garas, Michael Wallace, Bastiaan de Boer, Jacob George, Mohammed Eslam, Amy L. Phu et al. · 2023 · Hepatology
34. Cholecystectomy as a risk factor for metabolic dysfunction-associated fatty liver disease: unveiling the metabolic and chronobiologic clues behind the bile acid enterohepatic circulation
    Qi Li, Wanlin Dai, Jing Kong, Yu Tian, Yongsheng Chen · 2021 · Journal of Physiology and Biochemistry
35. Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease ( NAFLD )
    Danielle Brandman, Marie Boyle, Stuart McPherson, Mark L. Van Natta, Arun Jayant Sanyal, Kris V. Kowdley, Brent A. Neuschwander‐Tetri, Naga Chalasani, Manal F. Abdelmalek, Norah A. Terrault et al. · 2022 · Alimentary Pharmacology & Therapeutics
36. Performance of risk prediction models for post-operative mortality in patients undergoing liver resection
    Nadim Mahmud, Sarjukumar Panchal, Florence E. Turrentine, David Edward Kaplan, Victor M. Zaydfudim · 2022 · The American Journal of Surgery
37. Improvement in Non-alcoholic Fatty Liver Disease Score Correlates with Weight Loss in Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy: a Two-Centre Study from an Asian Cohort
    Zong Jie Koh, Hrishikesh Pandurang Salgaonkar, Jonathan Wei Jie Lee, Guowei Kim, Chun Hai Tan, Anton Kui Sing Cheng, Davide Lomanto, Jimmy Bok Yan So, Yock Young Dan, Asim Shabbir · 2018 · Obesity Surgery
38. Association of hand-grip strength and non-alcoholic fatty liver disease index in older adults
    Inhwan Lee, Jinkyung Cho, Jinkook Park, Hyun‐Sik Kang · 2018 · Physical Activity and Nutrition
39. Non‐invasive liver fibrosis scores are strongly associated with liver cancer mortality in general population without liver disease
    Ki‐Chul Sung, Michael Patrick Johnston, Mi Yeon Lee, Christopher D. Byrne · 2020 · Liver International
40. Machine learning models using non-invasive tests & B-mode ultrasound to predict liver-related outcomes in metabolic dysfunction-associated steatotic liver disease
    Heather Mary-Kathleen Kosick, Chris McIntosh, Chinmay Bera, Mina Fakhriyehasl, Mohamed Shengir, Oyedele Adewale Adeyi, Leila Amiri, Giada Sebastiani, Kartik S. Jhaveri, Keyur Patel · 2025 · Scientific Reports
41. NAFLD Associated Comorbidity
    Leonid Borisovich Lazebnik, Светлана Владимировна Туркина · 2021 · Экспериментальная и клиническая гастроэнтерология
42. Hepatic scavenger receptor BI is associated with type 2 diabetes but unrelated to human and murine non-alcoholic fatty liver disease
    Lisa Rein‐Fischboeck, Sabrina Krautbauer, Kristina Eisinger, Rebekka Pohl, Elisabeth M. Haberl, Thomas S. Weiß, Christa Buechler · 2015 · Biochemical and Biophysical Research Communications
43. Metabolic syndrome, non-alcoholic fatty liver disease and hepatocarcinoma
    Mario Serradilla Martin, José Ramón Oliver Guillén, Ana Palomares Cano, José Manuel Ramia · 2020 · Revista Española de Enfermedades Digestivas
44. Progression to Cirrhosis Leads to Improvement in Atherogenic Milieu
    Samarth Siddharth Patel, Mohammad Bilal Siddiqui, Anchalia Chandrakumaran, Viviana Rodríguez, Masoud Faridnia, Jose Hernandez Roman, Emily D. Zhang, Michael V. Patrone, Genta Kakiyama, Caroline H. Walker et al. · 2020 · Digestive Diseases and Sciences
45. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors
    Jake Peter Mann, Paul Carter, Matthew James Armstrong, Hesham K. Abdelaziz, Hardeep Uppal, Billal Patel, SURESH RAMA CHANDRAN, Ranjit S More, Philip Noel Newsome, Rahul Potluri · 2020 · PLoS ONE
46. Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population
    Guan Huei Lee, Wah Wah Phyo, Wai Mun Loo, Raymond Kwok, Taufique Ahmed, Asim Shabbir, Jimmy Bok Yan So, Calvin Jianyi Koh, Juanda Leo Hartono, Mark Dhinesh Muthiah et al. · 2020 · World Journal of Hepatology
47. Biochemical assessment of metabolic associated fatty liver disease
    Armando Raúl Guerra-Ruiz, Gregori Casals, Paula Iruzubieta, Marta Lalana, Alba Leis, Rosa María López, Javier Crespo, Manuel Morales‐Ruiz · 2021 · Advances in Laboratory Medicine / Avances en Medicina de Laboratorio
48. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective
    Mohammad Said Ramadan, Vincenzo Russo, Gerardo Nigro, Emanuele Durante‐Mangoni, Rosa Zampino · 2021 · Journal of Clinical Medicine
49. Nonmedicinal Interventions in Nonalcoholic Fatty Liver Disease
    Manuela G. Neuman, Radu M. Nanau, Lawrence B. Cohen · 2015 · Canadian Journal of Gastroenterology and Hepatology
50. γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study
    Joanne R Morling, Jonathan Andrew Fallowfield, Rachel M. Williamson, Christine M. Robertson, Stephen Glancy, Indra Neil Guha, Mark W. J. Strachan, Jackie F. Price · 2015 · Diabetologia
51. Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis
    Dana L. Sharma, Hari Vishal Lakhani, Rebecca L. Klug, Brian Snoad, Rawan El-Hamdani, Joseph I. Shapiro, Komal Sodhi · 2017 · Journal of Clinical & Cellular Immunology
52. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease
    Francesco Tovoli, S. Ferri, Fabio Piscaglia · 2020 · Current Pharmaceutical Design
53. Assessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events
    Sara Saki, Nader Saki, Hossein Poustchi, Reza Malekzadeh · 2020 · Middle East Journal of Digestive Diseases
54. Prognostic value of FIB-4 and NFS for cardiovascular events in patients with and without NAFLD
    Jun Zhang, Lin Li, Ling Lin, Yifan Wu, Lifen Hu, Zhaolan Feng, Deju Zhang, Ting Fu, Huilei Zhao, Xiaoping Yin et al. · 2025 · BMC Public Health
55. Inflammatory Protein Signatures as Predictive Disease-Specific Markers for Non-Alcoholic Steatohepatitis (NASH)
    Nadella Mounika, Suraj Bhausaheb Mungase, Shivangi Verma, Savneet Kaur, Utpal Jyoti Deka, Tarini Shankar Ghosh, Ramu Adela · 2024 · Inflammation
56. Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review
    Mattia Amoroso, Salvador Augustín, Sven Moosmang, Isabella Gashaw · 2024 · Journal of Molecular Medicine
57. Noninvasive diagnosis in alcohol‐related liver disease
    Alia Hadefi, Delphine Degré, Eric Trépo, Christophe Moreno · 2020 · Health Science Reports
58. Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis
    Mark Daniel DeBoer, Boya Lin, Stephanie L. Filipp, Kenneth J. Cusi, Matthew J. Gurka · 2020 · Nutrition Research
59. Predictive Scores in Primary Biliary Cirrhosis
    Arndt Weinmann, Thomas Sattler, Hans-Peter Unold, Annette Grambihler, Andreas Teufel, Sandra Koch, Marcus Schuchmann, Stefan Biesterfeld, Marcus‐Alexander Wörns, Peter R. Galle et al. · 2014 · Journal of Clinical Gastroenterology
60. Fatty liver disease: Disparate predictive ability for cardiometabolic risk and all-cause mortality
    Altan Onat · 2015 · World Journal of Gastroenterology
61. Inflammatory biomarkers and risk of atherosclerotic cardiovascular disease
    En Yu, Hsin‐Yin Hsu, Chun-Yuan Huang, Lee‐Ching Hwang · 2018 · Open Medicine
62. The diagnosis of nonalcoholic fatty liver disease should carry important prognostic information
    Ian A.C. Rowe, Richard Parker · 2019 · Nature Reviews Gastroenterology & Hepatology
63. Association of the Non‐Alcoholic Fatty Liver Disease Fibrosis Score with subclinical myocardial remodeling in patients with type 2 diabetes: A cross‐sectional study in China
    Nengguang Fan, Xiaoying Ding, Qin Zhen, Liping Gu, Aifang Zhang, Tingting Shen, Yufan Wang, Yongde Peng · 2020 · Journal of Diabetes Investigation
64. Associations of liver volume and other markers of hepatic steatosis with all‐cause mortality in the general population
    Muhammad Tayyab Naeem, Marcello Ricardo Paulista Markus, Mohammed Mousa, Sabine Schipf, Marcus Dörr, Antje Steveling, Ali Alexander Aghdassi, Jens‐Peter Kühn, Marie‐Luise Kromrey, Matthias A. Nauck et al. · 2021 · Liver International
65. Nonalcoholic fatty liver disease represents a greater metabolic burden in patients with atherosclerosis
    Jie Han, Yong Wang, Zhongshang Yuan, Lu Liu, Meng Zhao, Qingbo Guan, Haiqing Zhang, Qiu Li, Jin Xu, Ling Gao et al. · 2019 · Medicine
66. Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
    Mohamed El‐Kassas, Abeer Awad, Mohamed Elbadry, Juan Pablo Arab · 2024 · Seminars in Liver Disease
67. New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ermina Stratina, C Stanciu, Robert Năstasă, Sebastian Zenovia, Remus Stafie, Adrian Rotaru, Tudor Cuciureanu, Cristina Maria Muzica, Catalin Victor Sfarti, Irina Gîrleanu et al. · 2024 · Diagnostics
68. Association between composite dietary antioxidant index and fatty liver index among US adults
    Meng Zheng, Chaochen Li, Jia Fu, Long Bai, Jinghui Dong · 2024 · Frontiers in Nutrition
69. Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease
    Angelo Armandi, Elisabetta Bugianesi · 2023 · Clinics in Liver Disease
70. Emerging new standard for non-invasive assessment of liver disease mortality in non-alcoholic fatty liver disease
    S. Loo, Wah‐Kheong Chan · 2017 · HepatoBiliary Surgery and Nutrition
71. Cardiovascular Disease Risk and Statin Use Among Adults with Metabolic Dysfunction Associated Fatty Liver Disease
    Aaron Justin Yeoh, Ramsey C Cheung, Aijaz Ahmed, Amit S. Chitnis, Albert Do, Robert J. Wong · 2023 · The American Journal of Medicine
72. Association of fatty liver disease with mortality outcomes in an Eastern Finland male cohort
    Olubunmi Olubamwo, Jyrki K. Virtanen, Jussi Pihlajamäki, Tomi‐Pekka Tuomainen · 2019 · BMJ Open Gastroenterology
73. Неалкогольная жировая болезнь печени: особенности метаболических изменений на разных этапах развития болезни
    Yu.М. Stepanov, N.V. Nedzvetskaya, Victoria B. Yagmur, І.А. Кленіна · 2018 · GASTROENTEROLOGY
74. Non-invasive fibrosis assessments of non-alcoholic fatty liver disease associated with low estimated glomerular filtration rate among CKD patients: the Fukuoka Kidney disease Registry Study
    Masatoshi Hara, Shigeru Tanaka, Kumiko Torisu, Yuta Matsukuma, Akihiro Tsuchimoto, Masanori Tokumoto, Hiroaki Ooboshi, Toshiaki Nakano, Kazuhiko Tsuruya, Takanari Kitazono · 2021 · Clinical and Experimental Nephrology
75. Validity of routine biochemical and ultrasound scores for prediction of hepatic fibrosis and steatosis in NAFLD
    Rasha Eletreby, Zeinab Abdellatif, Yasmine Gaber, Ahmed Ramadan, Naglaa Ahmad, Hany Mahmoud Khattab, Mohamed Said, Yasmin Saad · 2021 · Egyptian Liver Journal
76. Assessment of fatty liver and its correlation with glycemic control in patients with type 2 diabetes mellitus attending Dessie Comprehensive Specialized Hospital, Northeast Ethiopia
    Gashaw Abebe, Daniel Ayanaw, Tiget Ayelgn Mengstie, Gashaw Dessie, Tabarak Malik · 2022 · SAGE Open Medicine
77. The association between thyroid hormones and MAFLD is mediated by obesity and metabolic disorders and varies among MAFLD subtypes
    Hong Xia Fan, Lili Li, Zhenqiu Liu, Liou Cao, Xingdong Chen, Chen Suo, Tiejun Zhang · 2022 · Digestive and Liver Disease
78. Model for end‐stage liver disease Na Score predicts incident major cardiovascular events in patients with nonalcoholic fatty liver disease
    Tracey G. Simon, Uri Kartoun, Hui Zheng, Andrew Tan Chan, Raymond T. Chung, Stanley Y. Shaw, Kathleen E. Corey · 2017 · Hepatology Communications
79. Coffee consumption is not associated with prevalent subclinical cardiovascular disease (CVD) or the risk of CVD events, in nonalcoholic fatty liver disease: results from the multi-ethnic study of atherosclerosis
    Tracey G. Simon, Maria Esther Perez Trejo, Irfan Zeb, Alexis C. Wood, Robyn L. McClelland, Raymond T. Chung, Matthew Jay Budoff · 2017 · Metabolism
80. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
    Michael N. Doumas, Konstantinos P. Imprialos, Konstantinos Stavropoulos, Vasilios Gabriel Athyros · 2019 · Current Vascular Pharmacology
81. Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study
    Thierry Thévenot, Sophie Vendeville, Delphine Weil, L. Akkouche, Paul Calame, Clémence M. Canivet, Claire Vanlemmens, Carine Richou, Jean‐Paul Cervoni, Marie‐France Seronde et al. · 2022 · PLoS ONE
82. Association of leukocyte telomere length with non-alcoholic fatty liver disease in patients with type 2 diabetes
    Min Zhang, Manli Hu, Jiaojiao Huang, San-Shan Xia, Yan Yang, Kun Dong · 2019 · Chinese Medical Journal
83. Prognostic impact of the combination of serum transaminase and alkaline phosphatase determined in the emergency room in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
    Pyung Chun Oh, Young Sil Eom, Jeonggeun Moon, Ho‐Jun Jang, Tae‐Hoon Kim, Jon Suh, Min Gyu Kong, Sang‐Don Park, Sung Woo Kwon, Jae Yeol Choe et al. · 2020 · PLoS ONE
84. Association between Body Fat Distribution and Nonalcoholic Fatty Liver Disease/Fibrosis Based on Race/Ethnicity
    Donghee Kim, George T. Cholankeril, Aijaz Ahmed · 2024 · Journal of Obesity & Metabolic Syndrome
85. Association of liver fibrosis scores with all‐cause and cardiovascular mortality in patients with heart failure
    Ziyu Guo, Zixiang Ye, Qinfeng Xu, Yike Li, Jingang Zheng · 2024 · Clinical and Translational Science
86. Oxidized High-Density Lipoprotein Shows a Stepwise Increase as Fibrosis Progresses in Patients with Nonalcoholic Fatty Liver Disease
    Kouichi Miura, Naoshi Arai, Rie Goka, Naoki Morimoto, Shunji Watanabe, Norio Isoda, Hironori Yamamoto, Kazuhiko Kotani · 2021 · Antioxidants
87. Clinical and sociodemographic determinants of disease progression in patients with nonalcoholic steatohepatitis in the United States
    Leonardo Ruiz‐Casas, Gabriel Pedra, Anum Shaikh, Bethany Franks, Harpal S. Dhillon, João Diogo da Rocha Fernandes, Kamal Kant Mangla, Margarida Augusto, Jörn Markus Schattenberg, Manuel Romero‐Gómez · 2021 · Medicine
88. Cardiovascular Diseases and Non-Alcoholic Fatty Liver Disease: Relationship and Pathogenetic Aspects of Pharmacotherapy
    Нелидова Анастасия Владимировна, Maria A. Livzan, Н. А. Николаев, Кролевец Татьяна Сергеевна · 2022 · Rational Pharmacotherapy in Cardiology
89. Validation and Comparison of Two Dietary Indexes for Predicting Nonalcoholic Fatty Liver Disease in US Adults
    Rui Li, Zhongxue Chen · 2022 · Journal of Nutrition
90. Association Between Urinary Alpha1-Microglobulin Levels and Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study
    Juanwen Zhang, Xuyao Zhang, Ying Y. Zhao, Guocai Lv · 2017 · Annals of Nutrition and Metabolism
91. Differing clinical phenotype for higher alanine-aminotransferase (ALT) compared with high-risk NAFLD fibrosis score in type 2 diabetes mellitus
    Kathryn Williams, Kharis A. Burns, Stephen Morris Twigg · 2017 · Journal of Diabetes and its Complications
92. The interaction of nonalcoholic fatty liver disease and smoking on mortality among adults in the United States
    Karn Wijarnpreecha, Melissa Scribani, Donghee Kim, W. Ray Kim · 2019 · Liver International
93. Evaluation of liver transplant candidates with non-alcoholic steatohepatitis
    James Phillip Esteban, Amon Asgharpour · 2021 · Translational Gastroenterology and Hepatology
94. Peripheral Artery Disease and Risk of Fibrosis Deterioration in Nonalcoholic Fatty Liver Disease: A Prospective Investigation.
    Wen Zhu, Chanjuan Deng, Li Ping Xuan, Hua Jie Dai, Zhi Yun Zhao, Tian Ge Wang, Mian Li, Jie Li Lu, Yu Xu, Yu Hong Chen et al. · 2020 · PubMed
95. Non-alcoholic fatty liver disease is not independent risk factor for cardiovascular disease event: A cohort study
    Nima Motamed, Hossein Ajdarkosh, Maral Ahmadi, Dhayaneethie Perumal, Gholam Hossein Ashrafi, Mehdi Nikkhah, Amir Hossein Faraji, Mansooreh Maadi, Mahmoodreza Khoonsari, Nader Rezaie et al. · 2020 · World Journal of Hepatology
96. Addition of hyaluronic acid to the FIB‐4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in type 2 diabetes: The Edinburgh Type 2 Diabetes Study
    Sheila M. Grecian, Stela McLachlan, Jonathan Andrew Fallowfield, Peter Clive Hayes, Indra Neil Guha, Joanne R Morling, Stephen Glancy, Rachel M. Williamson, Rebecca M. Reynolds, Brian M. Frier et al. · 2021 · Obesity Science & Practice
97. The Leg Fat to Total Fat Ratio Is Associated with Lower Risks of Non-Alcoholic Fatty Liver Disease and Less Severe Hepatic Fibrosis: Results from Nationwide Surveys (KNHANES 2008–2011)
    Hyun Min Kim, Yong‐ho Lee · 2021 · Endocrinology and Metabolism
98. Ethanol extract of Pharbitis nil ameliorates liver fibrosis through regulation of the TGFβ1-SMAD2/3 pathway
    Hyun Jin Jung, Kyohee Cho, Sun Yeou Kim, Je Kyung Seong, Seung Hyun Oh · 2022 · Journal of Ethnopharmacology
99. Non-Alcoholic Fatty Liver Disease: Diagnosis and Investigation
    Fabio Nascimbeni, Paola Loria, Vlad Ratziu · 2014 · Digestive Diseases
100. Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (i). Nonalcoholic fatty liver disease and its association with cardiovascular disease
     Ángel Brea, Xavier Pintó, Juan Francisco Ascaso, Mariano Blasco, Ángel Díaz, Pedro González‐Santos, Antonio Hernández‐Mijares, Teresa Mantilla, Jesús Millán, Juan Pedro‐Botet · 2017 · Clínica e Investigación en Arteriosclerosis (English Edition)